Here are five key notes:
1. KOVANAZE is the first product developed by the Fort Collins, Colo.-based company St. Renatus.
2. Traditionally, the dental industry has used needle injected anesthetic. However, KOVANAZE is administered through a nasal spray, without the use of a needle.
3. KOVANAZE contains tetracaineHCl (an ester local anesthetic) and oxymetazolineHCl (a vasoconstrictor).
4. The nasal spray is a topical, tooth nerve anesthetic, developed for dental procedures involving the upper teeth.
5. St. Renatus specifies that the anesthetic is meant for restoratives procedures on Teeth 4 through 13 and A through J in adults and children who weigh more than 40 kilograms.
More articles on anesthesia:
MIT and Massachusetts General Hospital develop sensor for anesthesiologists: 5 takeaways
Medaxion raises $950k in financing: 4 notes
Sweet Dreams Nurse Anesthesia settles False Claims allegations for $1M+: 5 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
